Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
2014 · New England Journal of Medicine · 1,825 citations
https://doi.org/10.1056/nejmoa1406037
E
E. Levchenko
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
183
Papers
7.5K
Citations
21
h-index
28
i10-index
E. Levchenko is an academic researcher from Research Medical Center. The author has contributed to research in topics: Lung Cancer Diagnosis and Treatment & Lung Cancer Treatments and Mutations & Cancer Diagnosis and Treatment. The author has an h-index of 21, co-authored 156 publications.
ORCID: 0000-0003-3837-2515Papers by this author
worksFive-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
2019 · New England Journal of Medicine · 1,316 citations
https://doi.org/10.1056/nejmoa1904059
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
2018 · The Lancet Oncology · 193 citations
https://doi.org/10.1016/s1470-2045(18)30254-7
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
2016 · ESMO Open · 73 citations
https://doi.org/10.1136/esmoopen-2016-000068
117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study
2024 · Immuno-Oncology Technology · 9 citations
https://doi.org/10.1016/j.iotech.2024.100746
Y-type carinal reconstruction after sleeve right lower bilobectomy
2024 · JTCVS Techniques · 0 citations
https://doi.org/10.1016/j.xjtc.2024.05.008
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat